** Shares of drug developer HCW Biologics HCWB.O rise 252% to 97 cents
** HCWB says it received U.S. FDA's clearance to start clinical trial for treatment of moderate-to-severe alopecia areata, which is an autoimmune disease that causes sudden hair loss
** HCWB says drug HCW9302 is protein therapy that helps reduce inflammation and promote hair growth
** Co says if trial is successful, HCW9302 may also be used to treat other diseases, including skin conditions, arthritis, and diabetes
** More than 154 mln shares traded, 578x their 25-day moving average
** HCWB shares fell 62.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。